Improving the speed and accuracy of diagnosing neuropsychiatric disorders
MindScan will provide physicians with accurate diagnostic reports of neuropsychiatric disorders by applying its proprietary image processing algorithm to standard anatomical MRI brain scans. Physicians will use these reports to inform their diagnoses. We are currently raising capital to complete prospective clinical trials, achieve regulatory approval, and launch.
The scientific founders of MindScan developed this new technology with non-dilutive grants totaling $13.8 million. Published findings across five disorders show 90% to 100% accuracy versus “gold standard”, research grade diagnoses. We will initially complete two multi-center, prospective clinical trials to support regulatory approval and reimbursement. The first clinical trial will include children and adolescents newly presenting with symptoms of Attention-deficit/hyperactivity disorder (ADHD) or for whom the diagnosis remains unclear. The second clinical trial will include adolescents and adults and will discriminate between Bipolar Disorder and Schizophrenia for newly presenting patients and patients for whom the diagnosis remains unclear. After regulatory approval, we will launch in the U.S. and Europe in 2021.
Eric Sandquist, CEO and co-founder, will apply his healthcare general management and startup experience to ensure success. Co-founder Bradley Peterson, MD, an internationally known imaging expert, neuroscientist, and child psychiatrist, will provide scientific leadership and support adoption. Ravi Bansal, PhD, a leading imaging and computer scientist, will provide scientific and technical leadership.
Let's Start a Conversation
Please use the form below to contact us. You may also email or call us.